Unique ID issued by UMIN | UMIN000018866 |
---|---|
Receipt number | R000021819 |
Scientific Title | Phase IIb study of SNJ-1656; A dose-response study in patients with primary open angle glaucoma or ocular hypertension |
Date of disclosure of the study information | 2015/08/31 |
Last modified on | 2015/09/02 12:14:58 |
Phase IIb study of SNJ-1656; A dose-response study in patients with primary open angle glaucoma or ocular hypertension
A dose-response study of SNJ-1656 in patients with primary open angle glaucoma or ocular hypertension
Phase IIb study of SNJ-1656; A dose-response study in patients with primary open angle glaucoma or ocular hypertension
A dose-response study of SNJ-1656 in patients with primary open angle glaucoma or ocular hypertension
Japan |
Primary open-angle glaucoma (POAG) or Ocular hypertension (OH)
Ophthalmology |
Others
NO
To evaluate the dose-response relationship of ocular hypotensive efficacy and safety of SNJ-1656 0.003%, 0.01%, 0.03% or SNJ-1656 vehicle given b.i.d. for 4 weeks in patients with POAG or OH.
Safety,Efficacy
Mean change from baseline intraocular pressure (IOP) at week 4 (Hour 0 and 2)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Dose comparison
4
Treatment
Medicine |
0.003% SNJ-1656 instilled in both eyes, b.i.d. for 4 weeks.
0.01% SNJ-1656 instilled in both eyes, b.i.d. for 4 weeks.
0.03% SNJ-1656 instilled in both eyes, b.i.d. for 4 weeks.
Vehicle instilled in both eyes, b.i.d. for 4 weeks.
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients had POAG or OH
2)IOP (hour 0)
POAG:IOP of >=18.0 mmHg and <= 31.0 mmHg
OH:IOP of >= 22.0 mmHg and <= 31.0 mmHg
3)Best corrected visual acuity of 0.5 or better
4)Patients who are completed designated washout at confirmation date of IOP
5)Change from baseline IOP (hour 0) at confirmation date of IOP <= 3.0 mmHg
1)Active retinal disease
2)History of keratorefractive surgery or filtering surgery
3)History of trabeculotomy or laser trabeculoplasty in the study eye
4)Highly visual field loss
5)Corneal abnormalities that would preclude accurate readings with an applanation tonometer
6)Ocular surgery within 90 days
7)Use of contact lenses
8)Any active ocular disease other than glaucoma or OH
9)Uncontrolled systemic disease (eg, hepatic, renal, cardiovascular or endocrine system disease)
10)Women who were pregnant, nursing or who were of childbearing potential, or planning a pregnancy
180
1st name | |
Middle name | |
Last name | Hidenobu Tanihara |
Kumamoto university
Department of Ophthalmology, Faculty of Life Sciences
1-1-1, Honjo, Chuo-ku, Kumamoto city 860-8556, Japan
096-373-5247
ganka@kumamoto-u.ac.jp
1st name | |
Middle name | |
Last name | Yoko Minagawa |
Senju Pharmaceutical co.,ltd.
Clinical Development
2-5-8,Hirano-machi, Chuo-ku, Osaka 541-0046, Japan
06-6201-9605
yoko_minagawa@senju.co.jp
Senju Pharmaceutical co.,ltd.
Senju Pharmaceutical co.,ltd.
Profit organization
NO
2015 | Year | 08 | Month | 31 | Day |
Unpublished
Completed
2009 | Year | 06 | Month | 01 | Day |
2009 | Year | 07 | Month | 01 | Day |
2015 | Year | 08 | Month | 31 | Day |
2015 | Year | 09 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021819
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |